Standard premedication

PreclinicalSmall molecule

Standard premedication is one of 6 small molecule programs targeting Gynecologic Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gynecologic CancerNot yet recruiting

Gynecologic CancerPreclinical

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Gynecologic Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

2 2

Paraplatin

AAvyxa

Phase 2

2 3

SSGJ-707

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 2

1 4

CD70 CAR-T Cells

CChongqing Precision Biotech Co., Ltd

Phase 1

1 5

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

—6

Standard premedication

SSeoul National University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Ovarian Cancer

NCT06977594

Clinical

Trials by Indication[1]

Trial1 trial

ANti-Oxidant in Variant Angina (ANOVA) Trial

Unknown status·SSeoul National University Hospital·Phase 4·NCT03228238·300 enrolled

Ovarian Cancer1 trial

A Randomized, Placebo-controlled, Parallel-group, Open-label Trial to Evaluate the Efficacy of Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Patients With Gynecologic Cancer

Recruiting·SSeoul National University Hospital·Preclinical·NCT06977594·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard premedication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard premedication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard premedication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

Standard premedication

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Trial1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News